FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1623-1625 November 25, 1993 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

X-linked lymphoproliferative disease is characterized by vulnerability to diseases induced by the Epstein-Barr virus, including life-threatening infectious mononucleosis, hypogammaglobulinemia, aplastic anemia, and B-cell non-Hodgkin's lymphoma. It is uniformly fatal by the age of 40 years¹.

Bone marrow transplantation has the potential to correct this defect and has been performed with HLA-matched family members or unrelated persons as donors. One patient had a return of serum IgG1 and IgG3 concentrations to normal but died of an adenovirus infection 84 days after bone marrow transplantation². Two other patients died 23 and 60 days after bone marrow transplantation as a result . . . [Full Text of this Article]

Case Report

Methods

Results

Discussion

Source Information

From the Departments of Haematology, Oncology, and Bone Marrow Transplantation, Prince of Wales Children's Hospital, Sydney, Australia (M.R.V., R.L.-P.-T., V.B., D.F.); the University of New South Wales, Sydney, Australia (M.R.V.); the Institut de Protection et de Surete Nucleaire, Paris (D.T.); the Departments of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (D.P.); and the Hopital Saint Louis, Paris (E.G.). David Purtilo, M.D., is deceased.

Address reprint requests to Professor Vowels at the Prince of Wales Children's Hospital, Randwick, 2031, NSW, Australia.

References

Related Letters:

Correction of X-Linked Lymphoproliferative Disease by Stem-Cell Transplantation
Ende M., Ende F. I., Vowels M. R., Duffy B., Lam-Po-Tang R., Ford D.
Extract | Full Text  
N Engl J Med 1994; 330:1159, Apr 21, 1994. Correspondence

This article has been cited by other articles:

• Li, G., Kim, Y.-J., Broxmeyer, H. E. (2005). Macrophage Colony-Stimulating Factor Drives Cord Blood Monocyte Differentiation into IL-10highIL-12absent Dendritic Cells with Tolerogenic Potential. J. Immunol. 174: 4706-4717 [Abstract] [Full Text]  
• Milone, M. C., Tsai, D. E., Hodinka, R. L., Silverman, L. B., Malbran, A., Wasik, M. A., Nichols, K. E. (2005). Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105: 994-996 [Abstract] [Full Text]  
• Issaragrisil, S., Visuthisakchai, S., Suvatte, V., Tanphaichitr, V. S., Chandanayingyong, D., Schreiner, T., Kanokpongsakdi, S., Siritanaratkul, N., Piankijagum, A. (1995). Transplantation of Cord-Blood Stem Cells into a Patient with Severe Thalassemia. NEJM 332: 367-369 [Full Text]  
• Ende, M., Ende, F. I., Vowels, M. R., Duffy, B., Lam-Po-Tang, R., Ford, D. (1994). Correction of X-Linked Lymphoproliferative Disease by Stem-Cell Transplantation. NEJM 330: 1159-1159 [Full Text]